Literature DB >> 11736772

The effect of an infusion of esmolol on the incidence of myocardial ischaemia during tracheal extubation following coronary artery surgery.

S M Kurian1, R Evans, N O Fernandes, K M Sherry.   

Abstract

The aim of this randomised controlled study was to determine whether an esmolol infusion affected the incidence of ST segment changes during weaning from intermittent positive pressure ventilation and tracheal extubation after coronary artery surgery. Thirty-one patients received an infusion of esmolol 0-300 microg x kg(-1) x min(-1) and 37 patients comprised the control group. ST segment changes were monitored using a continuous ambulatory surveillance system. The electrocardiogram, direct arterial pressure and pulse oximetry were monitored continuously. The period of analysis was from 120 min before until 180 min after tracheal extubation. Three patients in the esmolol group developed myocardial ischaemia during the study period compared with 12 in the control group (p = 0.05). Heart rate increased with time during the study period (p = 0.002) in the control group but was unchanged in the esmolol group. Mean heart rate was significantly higher in the control group than in the esmolol group from 40 min before until 180 min after tracheal extubation. Seven patients in the esmolol group suffered adverse events related to the esmolol infusion. Although the use of esmolol reduced the incidence of myocardial ischaemia, the incidence of adverse effects makes it unsuitable prophylaxis for patients after coronary artery surgery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11736772     DOI: 10.1046/j.1365-2044.2001.02318.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  9 in total

Review 1.  Possible indications of beta-blockers in the perioperative period other than prevention of cardiac ischemia.

Authors:  Yuji Kadoi; Shigeru Saito
Journal:  J Anesth       Date:  2010-02       Impact factor: 2.078

2.  Answering letter to remark of Dr's Frank and Fitzgerald.

Authors:  Günther Krumpl
Journal:  Eur J Clin Pharmacol       Date:  2018-01-10       Impact factor: 2.953

3.  Adequacy of control of preoperative hypertension can affect landiolol-induced hemodynamic changes in elderly patients during emergence from anesthesia.

Authors:  Yuji Kadoi; Tatsuo Horiuchi; Shinya Uchida; Shigeru Saito
Journal:  J Anesth       Date:  2011-01-14       Impact factor: 2.078

Review 4.  Clinical pharmacokinetics and therapeutic efficacy of esmolol.

Authors:  Donald B Wiest; Jason S Haney
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

5.  Effects of landiolol, a short-acting beta-1 blocker, on hemodynamic variables during emergence from anesthesia and tracheal extubation in elderly patients with and without hypertension.

Authors:  Masumi Miyazaki; Yuji Kadoi; Shigeru Saito
Journal:  J Anesth       Date:  2009-11-18       Impact factor: 2.078

Review 6.  Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2012-01-01       Impact factor: 11.431

Review 7.  Perioperative beta-blockers for preventing surgery-related mortality and morbidity.

Authors:  Hermann Blessberger; Juergen Kammler; Hans Domanovits; Oliver Schlager; Brigitte Wildner; Danyel Azar; Martin Schillinger; Franz Wiesbauer; Clemens Steinwender
Journal:  Cochrane Database Syst Rev       Date:  2018-03-13

8.  Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing cardiac surgery.

Authors:  Hermann Blessberger; Sharon R Lewis; Michael W Pritchard; Lizzy J Fawcett; Hans Domanovits; Oliver Schlager; Brigitte Wildner; Juergen Kammler; Clemens Steinwender
Journal:  Cochrane Database Syst Rev       Date:  2019-09-23

9.  Landiolol for managing atrial fibrillation in post-cardiac surgery.

Authors:  Jean-Luc Fellahi; Matthias Heringlake; Johann Knotzer; William Fornier; Laure Cazenave; Fabio Guarracino
Journal:  Eur Heart J Suppl       Date:  2018-01-08       Impact factor: 1.803

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.